News from carisma therapeutics inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 25, 2022, 11:00 ET Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, has appointed ...

Apr 08, 2022, 13:25 ET Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced...

Jan 10, 2022, 06:30 ET Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Moderna Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a...

Jan 05, 2022, 10:00 ET Carisma Therapeutics to Participate in 40th Annual J.P. Morgan Healthcare Conference

Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that Steven Kelly, President and...

Dec 06, 2021, 08:01 ET Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study

Carisma Therapeutics., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today...

Nov 29, 2021, 08:01 ET Carisma Therapeutics Appoints Sanford Zweifach as Chairman to Board of Directors

Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today...

Nov 12, 2021, 12:10 ET Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented...

Nov 01, 2021, 08:01 ET CARISMA Announces Multiple Abstracts Accepted for Presentation at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced...

Sep 22, 2021, 08:01 ET CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced...

Jun 08, 2021, 08:01 ET CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced...

Apr 28, 2021, 08:00 ET CARISMA Therapeutics to Present Data at The American Society of Gene & Cell Therapy 24th Annual Meeting

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced...

Apr 26, 2021, 08:00 ET CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today...

Apr 09, 2021, 08:01 ET CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced...

Mar 18, 2021, 08:00 ET CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pennsylvania (Penn) and focused on discovering...

Mar 01, 2021, 08:01 ET CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second...

Jan 07, 2021, 08:01 ET CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has...

Nov 09, 2020, 08:00 ET CARISMA to Present New Data at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new...

Oct 08, 2020, 09:00 ET CARISMA Therapeutics to Present at Upcoming Healthcare Industry Conferences

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the...

Oct 05, 2020, 09:00 ET CARISMA Therapeutics to Participate in Upcoming Investor Conferences

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the...

Jul 30, 2020, 09:00 ET CARISMA Therapeutics to Participate in Upcoming Investor Conferences

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the...

Jul 27, 2020, 03:00 ET CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S....

May 21, 2020, 10:49 ET Carisma Therapeutics to Present and Meet with Potential Investors at Upcoming Healthcare Investor Conferences

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the...

May 15, 2020, 09:36 ET New Data Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, shares details from new data ...

Mar 23, 2020, 12:42 ET First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Nature...

Feb 28, 2020, 16:01 ET Carisma Therapeutics to Present at March Scientific and Investor Conferences

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the...